Sorry, frenchbroad, your question to me got buried in my "to respond list."
My estimates for a small lab are much more modest, maybe 3/4 to one million to start with a couple of post docs and maybe 1/2 million to 3/4 million annually. Small stuff, not in vivo testing; no live animals, laminar air flow rooms, or other cost boosters. In other words no tests or experiments, performed on living things, human or animal. Just basic lab for in vitro work. I know this would be cost prohibitive in terms of more dilution and would have had to been a significant goal very early on, when the pps measured in dollars not dimes. Or IPIX would have had to choose to attempt to pay for a lab with licenses (We have no way of knowing if this was tried and failed, or not really tried). Just sayin' this decision or probably set of non-decisions meant that IPIX would mainly be a shell investment, and not a real company that did things or rather studies things. Serious product issues such as the effectiveness of Kevetrin, or Brilacidin's effectiveness with c-difficile, gram positive and gram negative infections, and many other issues will remain just matters of speculation on message boards or as subjects of excellent articles based mainly on non-invitro-study based evidence.
Market Data 
Markets 
AI
